By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Plexxikon Inc. 

91 Bolivar Drive

Berkeley  California  94710  U.S.A.
Phone: 510-647-4000 Fax: 510-548-8014



Start Up

Company News
Daiichi Sankyo, Plexxikon Inc.'s Rare Disease Drug Shows Promise in Phase I Study 7/30/2015 5:58:15 AM
Plexxikon Inc. And Merck & Co. (MRK) To Collaborate On Combination Study Evaluating Investigational Immuno-Oncology Regimen 5/7/2015 10:19:38 AM
Plexxikon Inc. And Quantumleap Healthcare Collaborative Announce Selection Of PLX3397 For I-SPY 2 TRIAL In Breast Cancer 12/11/2014 8:00:33 AM
OncoSec Medical Inc. And Plexxikon Inc. Collaborate To Explore Combination Immunotherapy In Preclinical Tumor Studies 11/18/2014 12:35:42 PM
Plexxikon Inc. Announces Promising Preliminary PLX3397 Phase 1 Extension Data In Patients With Pigmented Villonodular Synovitis (PVNS) 5/15/2014 9:58:15 AM
Plexxikon Inc. Announces PLX3397 Data Presentations At American Society of Clinical Oncology 2014 Annual Meeting 5/15/2014 8:05:23 AM
Plexxikon Inc. Taps New CEO, COO 5/31/2013 8:43:22 AM
Plexxikon Inc. Announces Three-Year Survival in Zelboraf-Treated Metastatic Melanoma Patients 11/9/2012 9:57:57 AM
Plexxikon Inc. Announces European Approval of Zelboraf® for the Treatment of Patients With BRAF Mutation-Positive Metastatic Melanoma 2/21/2012 6:49:47 AM
Plexxikon Inc. Advances Novel Targeted Treatment PLX3397 in Blood Cancer 12/13/2011 6:53:20 AM